MiNK Therapeutics, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for INKT, updated each market day.
INKT AI Sentiment
AI predicts MiNK Therapeutics, Inc. Common Stock stock is likely to decrease over the next 10 market days.
Prediction date: Sept. 22, 2026
Exact scores are in the SharePreds app
The precise prediction score for this stock, with buy and sell targets and a stop loss, updated every market day.
About MiNK Therapeutics, Inc. Common Stock
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
Sector
Exchange
Market Cap
$59,756,153
Cap Tier
Employees
15
Headquarters
NEW YORK, NY
Listed Since
Oct. 15, 2021
Website
INKT Sentiment Trend: Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
INKT Volatility
MiNK Therapeutics, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings: this can present both opportunity and risk for traders.
